You are here

Article Text

Article menu
Download PDFPDF
Recent advances in clinical practice
STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?
  1. T Asselah1,
  2. L Rubbia-Brandt2,
  3. P Marcellin1,
  4. F Negro3
  1. 1Service d’Hépatologie and INSERM CRB3, Hôpital Beaujon, Clichy, France
  2. 2Service de Pathologie Clinique, Hôpital Universitaire, Genève, Switzerland
  3. 3Services de Pathologie Clinique, de Gastroentérologie et d’Hépatologie, Hôpital Universitaire, Genève, Switzerland
  1. Correspondence to:
    Dr P Marcellin
    Service d’Hépatologie and INSERM CRB3, Hôpital Beaujon, Clichy 92 110, France; patrick.marcellin@bjn.ap-hop-paris.fr

https://doi.org/10.1136/gut.2005.069757

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    SUMMARY

    Hepatic steatosis is a common histological feature of chronic hepatitis C. Various factors are associated with hepatic steatosis, including obesity, high alcohol consumption, diabetes type II, and hyperlipidaemia. These factors may contribute to steatosis in patients with chronic hepatitis C. In humans, hepatitis C virus (HCV) genotype 3 is more commonly associated with steatosis. In vitro studies and the transgenic mouse model have suggested that the HCV core protein (genotype 1) can induce lipid accumulation within hepatocytes.

    However, what is the relevance of steatosis in chronic hepatitis C? It seems that in certain populations, steatosis may be associated with fibrosis progression and this may be genotype specific. The mechanisms underlying this association are unknown; neither is it clear whether this holds true for all patients or only a subgroup. Indeed, after antiviral treatment, virus related steatosis disappears whereas the host associated steatosis remains unaffected.

    This review describes and discusses the basic and clinical aspects of the relationship between steatosis and progression of fibrosis, and response to treatment in patients with chronic hepatitis C.

    INTRODUCTION

    HCV is a major cause of chronic liver disease with about 170 million people infected worldwide. The severity of disease varies widely from asymptomatic chronic infection to cirrhosis and hepatocellular carcinoma.

    Non-alcoholic fatty liver disease (NAFLD) represents a spectrum from simple steatosis at one end to severe inflammation with extensive fibrosis or cirrhosis at the other. Hepatic steatosis without inflammation is thought to have a good prognosis but non-alcoholic steatohepatitis (NASH) can progress to cirrhosis in a significant proportion of cases.

    Hepatic steatosis is also a common histological feature of chronic hepatitis C but may be independently associated with obesity, high alcohol consumption, type II diabetes, and hyperlipidaemia and, when these occur, may contribute to steatosis in patients with chronic hepatitis C. In this review we will …

    View Full Text

    Linked Articles